美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

BlossomHill Therapeutics

16.38

+0.58003.67%

盘后：16.380.00000.00%19:30 EDT

成交量：11.14万

成交额：180.68万

市值：5.02亿

市盈率：-6.70

高：16.50

开：16.00

低：15.75

收：15.80

52周最高：17.25

52周最低：15.25

股本：3,064.37万

流通股本：937.50万

量比：0.45

换手率：1.19%

股息：- -

股息率：- -

每股收益(TTM):-2.4440

每股收益(LYR):-24.8342

净资产收益率：--

总资产收益率：--

市净率：-3.30

市盈率(LYR):-0.66

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

BlossomHill Therapeutics

交易所：

NASDAQ

成立时间：

2020

员工人数：

- -

公司地址：

10255 Science Center Drive,Suite 200,San Diego,California,United States

官网：

http://www.bhtherapeutics.com

邮编：

92121

电话：

传真：

- -

简介：

BlossomHill Therapeutics, Inc.于2020年6月22日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，应用基于化学的合理药物设计方法来开发创新的小分子药物，以解决癌症治疗中未满足的重大医疗需求。其科学创始人和团队在开发创新小分子药物方面有着良好的记录，这些药物克服了现有疗法的局限性，包括多种获得批准的疗法，这些疗法已经带来了转化的患者结果。

董事

名称

职位

J. Jean Cui

Chief Executive Officer and Director and President

Y. Peter Li

Executive Chairman and Director

Bihua Chen

Director

Carl L. Gordon

Director

John Schmid

Director

Sheila Gujrathi

Director

Sundeep Agrawal

Director

Timothy Stubbs

Director

股东

名称

职位

J. Jean Cui

Chief Executive Officer and Director and President

Jason Keyes

Chief Financial Officer and Executive Vice President

Geoff Oxnard

Chief Medical Officer and Executive Vice President

Vincent Liptak

Executive Vice President and General Counsel

Y. Peter Li

Executive Chairman and Director

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/BLSM/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BLSM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","market":"US","secType":"STK","nameCN":"BlossomHill Therapeutics","latestPrice":16.38,"timestamp":1787342400000,"preClose":15.8,"halted":0,"volume":111393,"hourTrading":{"tag":"盘后","latestPrice":16.38,"preClose":16.38,"latestTime":"19:30 EDT","volume":19,"amount":307.42,"timestamp":1787355008098,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03670886075949356,"floatShares":9375000,"shares":30643700,"eps":-2.444,"marketStatus":"休市中","change":0.58,"latestTime":"08-21 16:00:00 EDT","open":16,"high":16.5,"low":15.75,"amount":1806784.4346299998,"amplitude":0.047468,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.444,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":15.8,"postHourTrading":{"tag":"盘后","latestPrice":16.38,"preClose":16.38,"latestTime":"19:30 EDT","volume":19,"amount":307.42,"timestamp":1787355008098,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4536184656458545},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","floatShares":9375000,"roa":"--","roe":"--","lyrEps":-24.834182,"volumeRatio":0.4536184656458545,"shares":30643700,"dividePrice":0,"high":16.5,"amplitude":0.047468,"preClose":15.8,"low":15.75,"week52Low":15.25,"pbRate":"-3.30","week52High":17.2488,"institutionHeld":0,"latestPrice":16.38,"eps":-2.444,"divideRate":0,"volume":111393,"delay":0,"ttmEps":-2.444,"open":16,"prevYearClose":16,"prevWeekClose":16.18,"prevMonthClose":16,"prevQuarterClose":16,"fiveDayClose":16.18,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BLSM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BLSM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BLSM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BLSM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BLSM","date":"2026-08-21","current":-6.702128,"percent":0.909091,"low":-7.12152,"twenty":-7.038752,"median":-6.955553,"eighty":-6.893907,"high":-2.788792,"avg":-6.617124,"sd":1.157195,"marketCap":484169828},"quantilePoints":[{"date":"2026-08-07","current":-6.897356,"twenty":-6.075643,"median":-4.843074,"eighty":-3.610505,"marketCap":490298560},{"date":"2026-08-14","current":-7.048236,"twenty":-7.038752,"median":-6.897356,"eighty":-6.893907,"marketCap":501023841},{"date":"2026-08-21","current":-6.811139,"twenty":-7.038752,"median":-6.955553,"eighty":-6.893907,"marketCap":484169828}],"updateTime":1787515995768},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":700852009,"yearFounded":2020,"address":"10255 Science Center Drive,Suite 200,San Diego,California,United States","zipCode":"92121","officePhone":"(858) 732-3880","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.bhtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0237},{"period":"ytd","weight":0.0237}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BlossomHill Therapeutics, Inc.于2020年6月22日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，应用基于化学的合理药物设计方法来开发创新的小分子药物，以解决癌症治疗中未满足的重大医疗需求。其科学创始人和团队在开发创新小分子药物方面有着良好的记录，这些药物克服了现有疗法的局限性，包括多种获得批准的疗法，这些疗法已经带来了转化的患者结果。","exchange":"NASDAQ","name":"BlossomHill Therapeutics","nameEN":"BlossomHill Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"BLSM\",market:\"US\",,,undefined,":{"directors":[{"name":"J. Jean Cui","position":"Chief Executive Officer and Director and President"},{"name":"Y. Peter Li","position":"Executive Chairman and Director"},{"name":"Bihua Chen","position":"Director"},{"name":"Carl L. Gordon","position":"Director"},{"name":"John Schmid","position":"Director"},{"name":"Sheila Gujrathi","position":"Director"},{"name":"Sundeep Agrawal","position":"Director"},{"name":"Timothy Stubbs","position":"Director"}],"executives":[{"name":"J. Jean Cui","position":"Chief Executive Officer and Director and President"},{"name":"Jason Keyes","position":"Chief Financial Officer and Executive Vice President"},{"name":"Geoff Oxnard","position":"Chief Medical Officer and Executive Vice President"},{"name":"Vincent Liptak","position":"Executive Vice President and General Counsel"},{"name":"Y. Peter Li","position":"Executive Chairman and Director"}]}}}